Skip to content
Bored Studies
Recruiting

REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

Arsenal Medical, Inc. · NCT02880163

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 15+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
40
US sites recruiting
2
Study start
August 7, 2025
Record last updated
November 10, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy is required.

Being studied: ResQFoam

Conditions: Hemorrhagic Shock; Trauma; Exsanguinating Hemorrhage; Shock; Traumatic

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Estimated age of 15 years or older (or subject weight estimated at greater than 50 kg if age is unknown)
  • Emergent, exsanguinating hemorrhage, from abdominal source as defined by:
  • Class III or IV hemorrhagic shock or
  • Assessment of Blood Consumption (ABC) score ≥ 2
  • Confirmation of abdominal hemorrhage by:
  • Direct visualization or
  • Positive Focused Assessment with Sonography in Trauma (FAST) or
  • Diagnostic Peritoneal Aspiration (DPA)
  • No other known, uncontrolled active sources of hemorrhage
  • Subject is intubated and sedated per local guidelines
  • Decision to administer foam is made within 30 minutes of admission to the emergency department.
  • Decision made to proceed to emergent laparotomy made within 30 minutes of admission to the emergency department.
  • Definitive surgical care is expected to occur within three hours of foam deployment
  • Subject must also be receiving concurrent transfusion of fluids or blood products.

Exclusion Criteria

  • Known or suspected major diaphragm injury
  • Known or suspected untreated pneumothorax
  • Known or suspected untreated hemothorax
  • Known or suspected blunt or penetrating cardiac or thoracic aortic trauma
  • Traumatic brain injury resulting in decapitation, visible brain matter or considered non- survivable based on initial physical exam
  • Received greater than five consecutive minutes of cardiopulmonary resuscitation in the pre-emergency department setting
  • Patients with Pulseless Electrical Activity
  • Known allergy to isocyanate
  • Known or suspected pregnancy
  • History of prior abdominal surgery or evidence of abdominal surgery (scars)
  • Disrupted abdominal wall that, in the opinion of the investigator would preclude ResQFoam from being adequately contained within the abdominal cavity
  • Subject in whom the abdominal aortic junctional tourniquet (AAJT) or Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) techniques have been used
  • Known Prisoners
  • Subjects with burns > 20% of total body surface area
  • Subject/legally authorized representative/subject family member purposefully opted out of participation in the study
  • Known Do Not Resuscitate order (DNR) or Physician Orders for Life Sustaining Treatment (POLST)
  • Known enrollment in another randomized, interventional study

Recruiting US locations

  • University of Alabama at Birmingham

    Birmingham, AL 35294

    Site contact: Madison Finch · 205-873-3652 · madisonfinch@uabmc.edu

  • University of Cincinnati

    Cincinnati, OH 45219

    Site contact: Dina Gomaa, MSc · 513-558-6305 · gomaada@ucmail.uc.edu

Study contacts (from the official record)

  • Carol Pekar, RAC · 508-523-5456 · cpekar@arsenalmedical.com
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam (NCT02880163) | Bored Studies